Rezum 治疗在年轻与老年男性中的四年真实世界功能与手术结局比较
该单中心回顾性研究纳入2017—2019年接受 Rezum 治疗的256例患者(年轻<65岁146例,老年≥65岁110例),比较两组4年随访的 IPSS、生活质量、最大尿流率、决策后悔及不良事件。两组各随访点 IPSS、生活质量、不良事件及4年再手术率均无显著差异,作者认为获益与风险相当,但老年组 Qmax 仅在3个月随访时有显著改善。
要点
- 两组各随访点 IPSS 与生活质量评分均无显著差异,且各自较基线均有显著改善。
- 老年组 Qmax 仅在3个月随访时较基线显著改善,年轻组各随访点均显著改善。
- 4年再手术率老年组4.0% vs 年轻组4.4%,差异无统计学意义(p=0.86)。
核心结论
- Rezum 治疗后4年,老年与年轻男性在 IPSS、生活质量及不良事件方面无显著差异,提示获益与风险相当;作者认为未来需进一步研究以明确 Rezum 对老年男性 Qmax 的影响。
研究设计与样本
- 单中心回顾性分析,纳入2017—2019年接受 Rezum 治疗的多种族人群256例,按年龄分为年轻组(<65岁,146例,57%)与老年组(≥65岁,110例,43%);多数为亚洲人(33.2%)或非西班牙裔黑人(28.9%)。
- 在基线及1、3、6、12和/或48个月评估 IPSS、生活质量、Qmax、决策后悔评分及不良事件;描述性统计采用 t 检验、卡方检验或 Mann-Whitney U 检验,结局变化按年龄分层采用 Wilcoxon 符号秩检验。
主要发现
- 合并队列4年时 IPSS、生活质量与 Qmax 较基线均有显著改善(均 p<0.05)。
- 两年龄组之间在任何随访点的 IPSS、生活质量或 Qmax 均无显著差异。
- 两组合并来看,IPSS 与生活质量自基线至所有随访点均有显著改善;年轻组 Qmax 自基线至所有随访点均显著改善,而老年组仅在3个月随访时观察到显著改善。
- 两组间不良事件或决策后悔均无显著差异。
- 4年再手术率两组间无显著差异:老年组4.0% vs 年轻组4.4%(p=0.86)。
临床怎么用
- 原文结论未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of urinary symptoms in elderly patients with benign prostatic hyperplasia (BPH) is complex given challenges with medications and invasive surgeries. Rezum, a minimally invasive water vapor therapy, is an emerging alternative. We compare real-world Rezum outcomes between young and elderly patients over 4 years. METHODS: We retrospectively analyzed a multiethnic population treated with Rezum at a single center between 2017-2019. Patients were stratified into young (<65 years) or elderly (≥65 years) cohorts. International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), decisional regret scores, and adverse events (AEs) were assessed at baseline, 1-, 3-, 6-, 12-, and/or 48-months. Descriptive statistics were compared using t-tests, Chi-squared, or Mann-Whitney U tests. Changes in outcomes were assessed using Wilcoxon signed-rank tests, stratified by age. RESULTS: 256 patients - 146 (57%) young and 110 (43%) elderly - were included. The majority were Asian (33.2%) or non-Hispanic Black (28.9%). Significant improvements were observed in the combined cohort at 4-years in IPSS, QoL, and Qmax when compared to baseline (all p < 0.05). Between the age cohorts, there were no significant differences in IPSS, QoL, or Qmax at any follow-up. Within both cohorts, significant improvements in IPSS and QoL were found from baseline to all follow-ups. In the young cohort, Qmax was significantly improved from baseline to all follow-ups while in the elderly cohort, this was observed only at the 3-month follow-up. No significant differences in AEs or regret was found between cohorts. There was no significant difference in 4-year surgical retreatment rates between cohorts (elderly 4.0% vs young 4.4%, p = 0.86). CONCLUSIONS: There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men.
引用
- Zhu M, Babar M, Hawks-Ladds N, et al. Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men. Prostate Cancer Prostatic Dis. 2023. PMID: 37620427. doi:10.1038/s41391-023-00703-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。